进化为七度耐火性髓瘤的过程涉及CD38,BCMA和GPRC5D的连续损失
C Riedhammer1, M Truger2, H Lee3
1Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany.
Leukemia
|February 17, 2026
概括
肝炎耐药多发性骨髓瘤 (MM) 是一种新的末期疾病,存活率较低. 基因组复杂性和抗原损失,包括BCMA,驱动耐药性,需要先进的诊断和新疗法.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 七度耐火性多发性骨髓瘤 (MM) 是一种新型的,超耐火性末期疾病.
- 患者对CD38抗体,免疫调节药物 (IMiD),蛋白酶体抑制剂 (PI) 和BCMA和GPRC5D导向免疫疗法具有抗性.
- 这种人群面临着极其糟糕的预后,有限的救援治疗选择.
研究的目的:
- 鉴定了七度耐火MM的基因组景观和临床结果.
- 研究治疗耐药性的机制,包括抗原损失.
- 为了确定治疗反应的潜在预测标记.
主要方法:
- 多中心队列研究包括37名耐性MM患者.
- 全基因组测序 (WGS) 用于识别基因组的改变.
- 免疫组织化学 (IHC) 来评估蛋白质表达 (例如,BCMA).
主要成果:
- 平均总生存时间为12.8个月;在救援疗法中,无进展生存时间很短.
- 观察到经常发生的双性瘤抑制基因事件 (例如TP53).
- 与对各种疗法的耐药性相关的基因组变化很常见 (IMiD 71%,BCMA 41%,GPRC5D 35%,CD38 12%).
- 几乎三分之一的患者同时发生BCMA (TNFRSF17) 和GPRC5D的损失.
- 在患者身上,WGS揭示了复杂的进化轨迹和明显的TNFRSF17/GPRC5D变异.
- IHC证实了由于基因组事件和其他机制导致的BCMA损失.
- 预测BCMA状态从BCMA重复治疗中获益.
结论:
- 肝炎耐药MM的特点是显著的基因组复杂性和抗原损失.
- 这些因素导致严重的治疗耐药性和不良结果.
- 综合基因组和IHC测试对于诊断和管理这一群体至关重要,指导新疗法的开发.
更多相关视频
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
734
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.8K
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Cancer Stem Cells and Tumor Maintenance
6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
